Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment

Launched by AUSL ROMAGNA RIMINI · Mar 23, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a personalized exercise program can improve the quality of life for patients with a specific type of lung cancer called non-small cell lung cancer, which is driven by certain genes known as oncogenes. Patients who are currently undergoing treatment will be divided into two groups: one group will follow a structured exercise plan with regular support from health experts, while the other will receive general advice about exercise without ongoing supervision. Throughout the study, participants will complete physical tests and answer questionnaires to track their progress, and their blood will be tested to see how their immune system responds to the exercise.

To be eligible for this trial, participants need to be at least 18 years old, have a good performance status (meaning they can carry out daily activities), and be receiving treatment for advanced lung cancer caused by specific gene mutations. Those who are unable to walk, have severe heart or respiratory issues, or certain other medical conditions may not qualify. Participants can expect to engage in a supportive exercise routine that is tailored to their abilities, with regular check-ins to help them stay on track and monitor their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older
• • 2. Willingness to provide written informed consent.
• • 3. Life expectancy \>12 weeks.
• • 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
• • 5. Body massa index \> 18.
• • 6. Oncogene-addicted (EGFR, ALK, ROS1, RET, BRAF) stage IV or III b not suitable for local treatment receiving first- or second-line systemic treatment (palliative radiotherapy and prior chemotherapy allowed). Patients undergoing treatment in clinical trials are excluded.
• Exclusion Criteria:
• • 1. Inability to walk.
• • 2. Immobility for more than 3 days before study enrollment.
• • 3. Previously untreated (non-irradiated or non-resected) symptomatic brain metastases.
• • 4. Severe cardiac impairment (e.g. cardiac insufficiency New York Heart Association (NYHA) \> III, myocardial infarction within the last three months, severe cardiac arrhythmias, high grade aortic stenosis).
• • 5. Severe respiratory failure.
• • 6. Uncontrolled pain.
• • 7. Bone metastasis inducing increased risk of pathological fractures.